Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
about
Efavirenz and the CNS: what we already know and questions that need to be answeredInhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.A targeted proteomics approach for profiling murine cytochrome P450 expression.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Consequences of a Chronic Exposure of Cultured Brain Astrocytes to the Anti-Retroviral Drug Efavirenz and its Primary Metabolite 8-Hydroxy Efavirenz.Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors.CNS penetration of ART in HIV-infected children.KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [14C]KAE609 in Healthy Male Subjects.Probing ligand structure-activity relationships in pregnane X receptor (PXR): efavirenz and 8-hydroxyefavirenz exhibit divergence in activation.
P2860
Q28085028-69AF6FE8-D756-4EB8-B468-90B3D043F9B0Q36571936-9ADDB132-49D4-415D-A1FA-FBBC9281809FQ37707721-97642377-5E09-4AF9-BE65-216E87760B92Q38755666-1500DDC7-9902-4788-9B6E-D35440F6F464Q39364925-3AEC4164-928B-48FD-9219-5A970AE375E4Q40531475-27E747B3-B58C-42D8-BA0D-C9597A236524Q40694902-DC9E1319-2E01-4E93-AA3A-06C8C99BB4ECQ40825222-EA446567-D701-4B7A-B131-3E3BC415FA30Q41208022-9F1AF517-9656-4DE6-8A5B-DA8E091E1B98Q41602074-99D10C4B-C82A-47F3-A5AD-F25EF0C63F1BQ43419116-42BD9DEA-2637-4A2B-93EB-984718C715DAQ45324155-959DB2EE-3C60-4AB3-B690-9DF638DF59E0Q47416079-6E271C53-D179-4579-ABAB-636DA8495227Q47949881-5690016B-8875-408D-B65E-8597DC95C1C2Q50070843-E22CF395-EF32-45B6-A356-854187DC17D1
P2860
Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Compartmentalization and antiv ...... asma, and cerebrospinal fluid.
@ast
Compartmentalization and antiv ...... asma, and cerebrospinal fluid.
@en
type
label
Compartmentalization and antiv ...... asma, and cerebrospinal fluid.
@ast
Compartmentalization and antiv ...... asma, and cerebrospinal fluid.
@en
prefLabel
Compartmentalization and antiv ...... asma, and cerebrospinal fluid.
@ast
Compartmentalization and antiv ...... asma, and cerebrospinal fluid.
@en
P2093
P2860
P356
P1476
Compartmentalization and antiv ...... asma, and cerebrospinal fluid.
@en
P2093
Craig W Hendrix
Jennifer L VanAusdall
Lindsay B Avery
Namandjé N Bumpus
P2860
P304
P356
10.1124/DMD.112.049601
P577
2012-11-19T00:00:00Z